2 completed, 1 active not recruiting. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 2, Active not recruiting 1 |
Follow tofersen: new trials by email Literature Review of tofersen trials Research Report on tofersen
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Learn If Tofersen (BIIB067) Can Delay ALS Symptoms and About Its Safety in Adults With a SOD1 Gene Mutation Who Have Not Yet Developed ALS Symptoms Tofersen, Placebo - Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation | Phase 3 | Active not recruiting | Biogen | 158 | 2021-05-17 | 2026-11-04 |
| Long-Term Evaluation of BIIB067 (Tofersen) Tofersen - ALS Caused by Superoxide Dismutase 1 (SOD1) Mutation | Phase 3 | Completed | Biogen | 139 | 2017-03-08 | 2025-08-29 |
| An Efficacy, Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Study of BIIB067 (Tofersen) in Adults With Inherited Amyotrophic Lateral Sclerosis (ALS) Tofersen, Placebo - Amyotrophic Lateral Sclerosis | Phase 3 | Completed | Biogen | 176 | 2016-01-20 | 2023-07-28 |
Amyotrophic Lateral Sclerosis (1)
Biogen (3)
Belgium (3) · Canada (3) · France (3) · Germany (3) · Italy (3) · Japan (3) · United Kingdom (3) · United States (3) · Australia (2) · Denmark (2) · Poland (2) · South Korea (2) · Brazil (1) · Spain (1) · Sweden (1)
PMID 36129998, PMID 41661214, PMID 32640130, PMID 35585374, PMID 42406382
2015 (1), 2016 (1), 2023 (1)